Study S001645

A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome

ClinicalTrials.gov record

Registration

Registration: NCT06595797
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 144
Start: 2024-09
Primary completion: 2025-12
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Obese Subjects With Polycystic Ovary Syndrome (PCOS)
Interventions: DRUG:HRS9531; DRUG:HRS9531placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Percentage change in body weight from baseline at 32 weeks of treatment [0week, 4week ,8week, 12week, 16week, 20week , 24week, 28week, 32week]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.